Phibro Animal Health (PAHC) Receivables (2013 - 2026)

Phibro Animal Health has reported Receivables for 14 years, with the latest figure at $252.7 million in Q2 2026.

• On a quarterly basis, Receivables rose 9.74% year-over-year to $252.7 million in Q2 2026; TTM through Jun 2026 was $252.7 million, a 9.74% increase from a year earlier, with the FY2026 full-year figure at $252.7 million, up 9.74% from the prior year.
• Receivables was $252.7 million for Q2 2026 at Phibro Animal Health, up from $221.5 million in the prior quarter.
• The five-year high for Receivables was $252.7 million in Q2 2026, with the low at $142.7 million in Q3 2022.
• Average Receivables over 5 years is $181.1 million, with a median of $167.6 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Receivables fell 2.93% in 2023, then surged 35.53% in 2025.
• Over 5 years, Receivables stood at $151.8 million in 2022, then retreated by 0.79% to $150.6 million in 2023, then rose by 27.33% to $191.8 million in 2024, then increased by 12.56% to $215.9 million in 2025, then climbed by 17.04% to $252.7 million in 2026.
• The last three Receivables figures came in at $252.7 million (Q2 2026), $221.5 million (Q1 2026), and $215.9 million (Q4 2025), per Business Quant data.